Arvinas, Inc. (NASDAQ:ARVN) Stock Has Consensus Target Price of $15.40 According to Brokerages

Arvinas, Inc. (NASDAQ:ARVN) has been given an average rating of “Moderate Buy” by the ten analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $15.18.

Several equities analysts have recently issued reports on ARVN shares. Evercore set a $14.00 price objective on shares of Arvinas in a research note on Monday, August 10th. Wedbush increased their target price on shares of Arvinas from $11.00 to $12.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Citigroup reduced their target price on shares of Arvinas from $24.00 to $21.00 and set a “buy” rating for the company in a report on Monday, August 10th. Wall Street Zen upgraded shares of Arvinas from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Zacks Research upgraded shares of Arvinas from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 9th.

Arvinas Stock Up 4.7%

NASDAQ:ARVN opened at $7.42 on Monday. The business’s 50-day moving average price is $7.98 and its 200 day moving average price is $9.63. Arvinas has a 52-week low of $6.74 and a 52-week high of $14.51. The firm has a market cap of $478.74 million, a P/E ratio of -30.92 and a beta of 1.81.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.10. Arvinas had a negative net margin of 3.45% and a negative return on equity of 2.06%. The company had revenue of $0.50 million during the quarter, compared to the consensus estimate of $12.39 million. During the same period in the prior year, the company earned ($0.48) EPS. Arvinas’s revenue was down 98.8% on a year-over-year basis. Sell-side analysts expect that Arvinas will post 0.15 EPS for the current year.

Institutional Investors Weigh In On Arvinas

Large investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Arvinas during the third quarter valued at approximately $26,000. Integrated Wealth Concepts LLC acquired a new position in Arvinas in the 2nd quarter worth approximately $48,000. Pinnacle Wealth Planning Services Inc. purchased a new position in Arvinas during the 3rd quarter worth approximately $45,000. Quantbot Technologies LP purchased a new position in Arvinas during the 2nd quarter worth approximately $85,000. Finally, Corient Private Wealth LP purchased a new position in Arvinas during the 2nd quarter worth approximately $95,000. 95.19% of the stock is owned by institutional investors.

Arvinas Company Profile

Arvinas, Inc is a clinical-stage biopharmaceutical company focused on developing medicines based on targeted protein degradation. The company’s proprietary PROTAC® protein degrader platform is designed to direct the body’s natural cellular machinery to selectively break down disease-causing proteins that may be difficult to address with conventional drug approaches.

Arvinas has concentrated its research and development efforts primarily on oncology, including hormone-driven cancers. Its pipeline has included vepdegestrant, an estrogen receptor protein degrader being developed for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, as well as other investigational degraders targeting cancer-related proteins.